What is Pulmonary Hypertension (PH)?
Pulmonary hypertension (PH) is a condition where blood pressure is increased in the arteries of the lungs. It is typically associated with left heart disease and classified as Group 2 PH. The lack of studies exploring the pathophysiology and therapies for Group 2 PH is linked to insufficient validated small-animal models.
Pre-clinical studies validating murine myocardial infarction model
Dr. Dayeh’s research group from the Montreal Heart Institute1 recently addressed this issue with a novel animal model. They induced heart failure by coronary artery ligation, which led to the development of pulmonary hypertension in mice. The findings were particularly interesting as it was discovered that myocardial infarction (MI) has an impact on pulmonary capacity, through alveolar and vascular remodelling evidenced by collagen deposition and cellular proliferation.
Four weeks after surgery, Dr. Dayeh and her team were able to assess specific lung characteristics in their subjects such as quasi-static compliance, quasi-static elastance, and respiratory system resistance. Since the flexiVent goes beyond traditional resistance and compliance measurements, it helps captures crucial details about the mechanical properties of conducting airways, terminal airways and parenchyma, providing a unique tool to perform a comprehensive assessment of Group 2 PH models and more!
Dayeh, Nour R., et al.1 Study outcomes showed:
- Myocardial infarction (MI) from coronary artery ligation is a validated mouse model of Group 2 PH
- Wall motion score index (WMSI) is an accurate predictive marker of PH
- Echocardiography in mice appears as a preferential method for the diagnosis and monitoring of Group 2 PH
1Dayeh, Nour R., et al. “Echocardiographic validation of pulmonary hypertension due to heart failure with reduced ejection fraction in mice.” Scientific reports 8.1 (2018): 1363.
More Publications featuring the flexiVent and other SCIREQ research systems.